MetaVia's new drug showed it can lower uric acid and liver fat in trial participants.

Nov 12, 2026, 1:05 PM ETTrialRead the original at Benzinga

Good for MTVA

The results show changes in uric acid, liver fat, weight, and blood sugar, supporting MetaVia's drug program. But the study was small, with 15 treated participants and 4 on placebo, and a larger trial is still planned.

MTVA · MetaVia Inc.

AI read · Good for MTVA

The AI's read

These changes suggest DA-1726 may affect several problems tied to liver and weight disease. That could support MetaVia's effort to develop a treatment. Still, the study was small and lasted 16 weeks. The larger Phase 2 study is planned for the second half of 2027, so patient benefit remains unproven.

Get alerts for MTVA

Follow MetaVia Inc. (MTVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MTVA

Free on the App Store and Google Play, or on the web.